NL-OMON35047已完成2 期
A phase II study to investigate the efficacy of RAD001 (Afinitor ®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma - THYRRAD
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Inclusion Criteria:
- •* Age > 18 years
- •* Karnofsky performance score > 70%
- •* Patients with differentiated thyroid carcinoma (i.e. papillary and follicular carcinomas)
- •* Patients must have undergone total thyroidectomy (and having received thyrosuppressive therapy afterwards)
- •* Patients with no RaI uptake in tumor as proven by RaI scintigraphy performed after prior RaI therapy
- •* Patients with insufficient RaI uptake as proven by progression of lesions despite accumulation of RaI
- •* Patients with a maximum cumulative dosis of RaI
- •* The patient has documented progressive disease (PD) on computerized tomography (CT), magnetic resonance imaging (MRI), bone scan or X-ray, per RECIST v1.1 at screening compared with a previous image done within 14 months of screening
- •* The subject has no other diagnosis of malignancy (unless non-melanoma skin cancer, carcinoma in situ of the cervix, or a malignancy diagnosed * 2 years previously) and currently has no evidence of malignancy (unless non-melanoma skin cancer or carcinoma in situ of the cervix).
- •* Patients with history of brain metastasis who are neurologically stable following definitive radiation and/or surgery and do not require corticosteroids will be permitted.;Laboratory Requirements - within 14 days prior to enrollment:
- •* Patients with adequate bone marrow function defined as ANC * 1.5 x 109/L, Platelets * 100 x 109/L, Hb * 5.6 mmol/L
- •* Patients with adequate liver function defined as serum bilirubin * 1.5 x ULN, ALT and AST * 2.5x ULN. Patients with known liver metastases are allowed to have an AST and ALT * 5x ULN.
- •* Patients with adequate renal function defined as serum creatinine * 2 x ULN.
- •* Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to the first dose of study drug.;Additional inclusion groups
- •Patients with progressive metastases or inoperable recurrent disease of undifferentiated (anaplastic) or medullary thyroid cancer will also have the opportunity to participate in this study, since there is a lack of therapeutic options for these patients. The same inclusion and exclusion criteria will be used, apart from the criteria on RaI therapy, since this is not applicable for undifferentiated or medullary thyroid cancer. We will analyse these patients as separate cohorts. Patients with undifferentiated or medullary thyroid cancer will be treated and evaluated according to the same criteria as the patients included with differentiated thyroid cancer. A minimum of 7 undifferentiated thyroid cancer patients and 7 medullary thyroid cancer patients will be analysed for response rate; if no responses are found in these patient groups, further investigation of RAD001 in undifferentiated or medullary thyroid cancer patients is not warranted.
排除标准
- •Exclusion Criteria:
- •* Patients receiving chemotherapy, immunotherapy, radiation therapy or any other investigational agent within 4 weeks of the first dose of study drug, or sunitinib and/or sorafenib within 2 weeks of the first dose of RAD001. Patients must have recovered from effects of prior therapy.
- •* Patients who have previously received RAD001 or other mTOR inhibitors.
- •* Patients with known hypersensitivity to RAD001 or other rapamycin analogs (sirolimus, temsirolimus), or to its excipients.
- •* Patients receiving chronic, systemic treatment with corticosteroids or another
- •immunosuppressive agent (except corticosteroids with a daily dosage equivalent to
- •prednisone * 20 mg for adrenal insufficiency). Patients receiving corticosteroids must be on a stable dose for * 4 weeks prior to the first dose of RAD001. Topical or inhaled corticosteroids are permitted.
- •* Patients with an active bleeding diathesis.
- •* Patients who have undergone major surgery within 4 weeks prior to starting study drug (e.g., intra-thoracic, intra-abdominal, or intra-pelvic), open biopsy, or significant traumatic injury, or who have not recovered from the side effects of any of the above.
- •* Patients with any severe and/or uncontrolled medical conditions such as unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction * 6 months, serious uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, active or uncontrolled severe infection, cirrhosis, chronic or persistent active hepatitis or severely impaired lung function.
- •* Uncontrolled diabetes
- •* Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not willing to use effective birth control methods.
研究者
相似试验
进行中（未招募）
不适用
A phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma - THYRRAD, CRAD001CNL08TPatients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma will be treated in a phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus).EUCTR2009-016669-27-NLeiden University Medical Center
尚未招募
2 期
Treatment of Abnormal Vaginal Discharge by giving Vaginal Wash.CTRI/2023/09/057996Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital Thanniruhalla BMRoad Hassan
已完成
2 期
A phase II study to investigate the efficacy of neoadjuvant erlotinib in patients with clinical stage I/II non-small cell lung cancer (NSCLC)early stage lung cancernon-small cell lung cancer stage I/II10038666NL-OMON29708Antoni van Leeuwenhoek Ziekenhuis55
已完成
2 期
Phase II study to examine efficacy prediction of Regorafenib with FDG-PET/CT in patients with treatment-refractory metastatic colorectal cancerColorectal CancerJPRN-UMIN000015563onprofit Organization Japan Clinical Cancer Research Organization20
招募中
1 期
Study Evaluating the Effects of ARO-RAGE in Healthy Subjects and Patients with Inflammatory Lung DiseaseInflammatory Lung DiseaseMedDRA version: 20.0Level: PTClassification code: 10003553Term: Asthma Class: 100000004855CTIS2023-509654-60-00Arrowhead Pharmaceuticals Inc.147